Fremanezumab for the preventive treatment of migraine

References

• GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–1259.
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808.
   PubMed Web of Science ®Google Scholar
• Foundation MR. Migraine facts - Migraine research foundation 2018. 2018 Nov 15. [ cited 2019 May 22]. Available from: https://migraineresearchfoundation.org/about-migraine/migraine-facts/.
   Google Scholar
• Buse DC, Lipton RB. Global perspectives on the burden of episodic and chronic migraine. Cephalalgia. 2013;33(11):885–890.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Munjal S, Alam A, et al. Migraine in America Symptoms and Treatment (MAST) study: baseline study methods, treatment patterns, and gender differences. Headache. 2018;58(9):1408–1426.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646–657.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53(4):644–655.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Lipton RB. Clinical course in migraine: conceptualizing migraine transformation. Neurology. 2008;71(11):848–855.
   PubMed Web of Science ®Google Scholar
• Estemalik E, Tepper S. Preventive treatment in migraine and the new US guidelines. Neuropsychiatr Dis Treat. 2013;9:709–720.
   PubMed Web of Science ®Google Scholar
• Saper JR, Da Silva AN. Medication overuse headache: history, features, prevention and management strategies. CNS Drugs. 2013;27(11):867–877.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31(3):301–315.
   PubMed Web of Science ®Google Scholar
• Sparrow A, Thakur S. Migraine: disease landscape & forecast. Decision Resources, LLC; 2018.
   Google Scholar
• American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1–18.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–349.
   PubMed Web of Science ®Google Scholar
• Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20(1):22–33.
   PubMed Web of Science ®Google Scholar
• Martelletti P. The application of CGRP(r) monoclonal antibodies in migraine spectrum: needs and priorities. BioDrugs. 2017;31(6):483–485.
   PubMed Web of Science ®Google Scholar
• Sacco S, Bendtsen L, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6.
   PubMed Web of Science ®Google Scholar
• Lambru G, Andreou AP, Guglielmetti M, et al. Emerging drugs for migraine treatment: an update. Expert Opin Emerg Drugs. 2018;23(4):301–318.
   PubMed Web of Science ®Google Scholar
• Teva Pharmaceuticals. AJOVY [prescribing information]. 2018.
   Google Scholar
• AIMOVIG™ [prescribing information]. Amgen; 2018.
   Google Scholar
• Dodick DW, Ashina M, Brandes JL, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026–1037.
   PubMed Web of Science ®Google Scholar
• Shi L, Lehto SG, Zhu DX, et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther. 2016;356(1):223–231.
   PubMed Web of Science ®Google Scholar
• EMGALITY® (prescribing information). Eli Lilly; 2018.
   Google Scholar
• Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13(11):1100–1107.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Walter S, Rapoport AM. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache. 2013;53(8):1230–1244.
   PubMed Web of Science ®Google Scholar
• Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6:573–582.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017 Apr;97(2):553–622.
   PubMed Web of Science ®Google Scholar
• Dodick DW. A phase-by-phase review of migraine pathophysiology. Headache. 2018;58(Suppl 1):4–16.
   PubMed Web of Science ®Google Scholar
• Melo-Carrillo A, Strassman AM, Nir RR, et al. Fremanezumab-a humanized monoclonal anti-CGRP antibody-inhibits thinly myelinated (Adelta) but not unmyelinated (C) meningeal nociceptors. J Neurosci. 2017 Nov 1;37(44):10587–10596.
   PubMed Web of Science ®Google Scholar
• Melo-Carrillo A, Noseda R, Nir RR, et al. Selective inhibition of trigeminovascular neurons by fremanezumab: a humanized monoclonal anti-CGRP antibody. J Neurosci. 2017;37(30):7149–7163.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015;79(6):886–895.
   PubMed Web of Science ®Google Scholar
• Armour KL, Clark MR, Williamson LM, inventors; Cambridge Enterprise Limited, assignee. Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis. United States patent US 7,597,889 B1. October 6, 2009.
   Google Scholar
• Bigal ME, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14(11):1081–1090.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Edvinsson L, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14(11):1091–1100.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. Jama. 2018;319(19):1999–2008.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113–2122.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, McAllister P, Ning X, et al. Safety and tolerability of fremanezumab for the prevention of migraine: a pooled analysis of Phases 2b and 3 clinical trials. Headache. 2019 Apr 12 Epub ahead of print. DOI:10.1111/head.13534.
   Google Scholar
• Silberstein SD, Dodick DW, Lindblad AS, et al. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. Neurology. 2012;78(13):976–984.
   PubMed Web of Science ®Google Scholar